The Platinum Study - Version 2.0, 9th July 2015
Research type
Research Study
Full title
Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities
IRAS ID
171020
Contact name
Robert Huddart
Contact email
Sponsor organisation
Institute of Cancer Research
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Testicular cancer is the most common cancer in young adults aged between 14-44 years. Platinum based regimens have resulted in dramatic improvements in cure rates. Over the last two decades, there has been increasing interest to evaluate longer term toxicities in survivors. Testicular cancer survivors receiving cisplatin based chemotherapy are also at risk of other toxicities that include pulmonary, renal, gonadal and those of the nervous system (neuropathy, ototoxicity) as well as increased risk of metabolic syndrome. There is a need to understand the aetiology or these toxicities and if possible modulate their risk of late- effects of treatment in survivors. Growing evidence is developing that the individuals risk of toxicity may be genetically determined but pharmaco-genomics in relation to testicular cancer is limited. This study aims to investigate factors leading to long term sequelae in survivors which compromise quality of life. The initial primary objectives of this proposal is to study molecular genetics of neurotoxicity and ototoxicity after treatment. We have been invited to join with 8 leading US sites in a consortium to investigate this issue. The project aims to collect clinical and biological data in over 3000 patients treated with cisplatin chemotherapy . This size of study is essential to have sufficient power to detect potential predisposing variants and requires collaboration to achieve.
We aim to contribute 400-600 patients who have had 3 – 6 cycles of cisplatin chemotherapy , are in remission and on follow up at the Royal Marsden.REC name
London - Surrey Borders Research Ethics Committee
REC reference
15/LO/1444
Date of REC Opinion
21 Sep 2015
REC opinion
Favourable Opinion